Rineterkib

ERK-IN-1 (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].

Research Areas >> Cancer

Signaling Pathways >> MAPK/ERK Pathway >> Raf

Signaling Pathways >> MAPK/ERK Pathway >> ERK

Signaling Pathways >> Stem Cell/Wnt >> ERK

RAF

ERK1

ERK2

ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1]. Animal Model: Calu-6 NSCLC xenograft tumor models in mice[1]. Dosage: 50, 75 mg/kg. Administration: Orally either daily (qd) or every other day (q2d) for 27 days. Result: Significantly reduced the tumor volume.

[1]. WO2018051306A1.